NASDAQ:MRUS 30 December 2025 - 8 May 2026

Genmab A/S dropped roughly 10% in Copenhagen Friday, after the Danish biotech posted a steep first-quarter profit decline. Higher costs from its Merus deal and stepped-up R&D spending canceled out a healthy bump in revenue. Around midday CEST, shares were quoted at 1,586.25 Danish crowns, down 9.8%, Cboe Europe data showed on MarketScreener.

Merus N.V. shares were halted on Tuesday after Nasdaq said the final merger step in Denmark’s Genmab’s $97-a-share cash acquisition closed before the market open, leaving the stock set for suspension on Dec. 31. Merus last traded around $90 late Monday, about 7% below its prior close, according to market data. NASDAQ Trader